Enhancing Effect of the Liver Extract and Flavin Adenin Dinucleotide Mixture on Anti-viral Efficacy of Interferon in Patients with Chronic Hepatitis C

この論文にアクセスする

この論文をさがす

著者

    • 斎藤 英胤 SAITO Hidetsugu
    • Department of Internal Medicine, School of Medicine, Keio University Department of Internal Medicine, School of Medicine, Keio University
    • 厚川 和裕 ATSUKAWA Kazuhiro
    • Department of Internal Medicine, School of Medicine, Keio University Department of Internal Medicine, School of Medicine, Keio University
    • 増田 哲也 MASUDA Tetsuya
    • Department of Internal Medicine, School of Medicine, Keio University Department of Internal Medicine, School of Medicine, Keio University
    • 土屋 雅春 TSUCHIYA Masaharu
    • Department of Internal Medicine, School of Medicine, Keio University Department of Internal Medicine, School of Medicine, Keio University
    • 石井 裕正 ISHII Hiromasa
    • Department of Internal Medicine, School of Medicine, Keio University Department of Internal Medicine, School of Medicine, Keio University

抄録

A combined preparation of liver extract and flavin adenin dinucleotide (FAD) (Adelavin<sup>®</sup>) has been widely used in patients with chronic liver diseases in Japan. One milliliter of this agent contains 15 μl of phenol-soluble phase of liver nucleic acid fraction and 10 mg of FAD. To examine the advantages of using this preparation in the elimination of hepatitis C virus (HCV) from patients with chronic hepatitis (CH)-C receiving interferon (IFN), 2 ml of this preparation was intravenously (n=9) or intramuscularly (n=8) administered daily for 5 days before 6 million units of IFN-α was intramuscularly injected once. Before and 48 hours after the injection of IFN, serum ALT, 2'5'-oligoadenylate synthetase (2'5-AS) activity, and HCV RNA levels were measured. The daily administration of this preparation alone for 5 days did not significantly change serum ALT, 2'S-AS activities, and HCV RNA levels. The 2'5-AS activities were significantly increased by IFN after the intravenous injection of this preparation (p<0.01), while an injection of IFN alone of this dose did not change its activities (n=10). HCV RNA levels were significantly decreased by IFN only after the administration of the preparation (intramuscular, p<0.01; intravenous, p<0.01). The effect of intravenous injection of this preparation was also elicited in patients with HCV genotype H and with HCV more than 10<sup>5</sup> copies/ml. These results suggest that this preparation may enhance the 2'5-AS production by IFN as a result of the increase in mitochondrial adenosin triphosphate production and may be a potent agent to enhance the anti-viral efficacy of IFN in patients with CH-C.

収録刊行物

  • Keio journal of medicine  

    Keio journal of medicine 45(1), 48-53, 1996-03-01 

    The Keio Journal of Medicine

参考文献:  14件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  4件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021985718
  • NII書誌ID(NCID)
    AA00710216
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00229717
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ